

BEST AVAILABLE COPY**REMARKS**

A first response to the Restriction Requirement was mailed on February 16, 2005. An inadvertent error resulted in the wrong sequence being elected in that response. This supplemental response is therefore being submitted to correct that error.

In response to the Restriction Requirement, applicants hereby elect the claims of Group II (claims 6-9, 26, 27, 29 and 34; drawn to isolated polypeptides) and the polypeptide of SEQ ID NO: 16. Table 1 (page 14) of the specification indicates that SEQ ID NO: 16 is encoded by the DNA sequence of SEQ ID NO: 4.


Claims 1-5, 10-24, 30, 32 and 33 have been withdrawn as being drawn to a non-elected invention. Claim 6 has been amended to remove reference to withdrawn claim 1. Claims 7 and 9 have been amended to remove reference to non-elected sequences, and claim 27 has been amended to correct a typographical error.

It is urged that support for all the above amendments may be found throughout the specification as originally filed and that none of the amendments constitute new matter. It is further submitted that the amendments are not being made for reasons of patentability and therefore do not give rise to prosecution history estoppel.

Applicants hereby reserve the right to rejoin method claims 25, 28 and 31 with the elected product claims once the product claims are found to be allowable.

Favorable consideration of the amended claims is respectfully requested.

Respectfully submitted,


Janet Sleath
Registration No. 37,007

Date: February 18, 2005
SPECKMAN LAW GROUP PLLC

20601